ArticlePloS one2025
The association of POSTN with postoperative recurrence risk in early-stage lung adenocarcinoma: From gene networks to cellular functions.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePeriostin (POSTN) has been identified as a biomarker highly correlated with the risk of recurrence of lung adenocarcinoma (LUAD). Increasing the understanding of POSTN's role in LUAD recurrence may facilitate the development of more effective clinical interventions.
methodsFirstly, Weighted Gene Co-expression Network Analysis (WGCNA) analysis was used to identify key genes related to LUAD disease recurrence. Subsequently, the diagnostic performance of these genes was evaluated using Receiver Operating Characteristic (ROC) curves and validated using external datasets. The most effective genes were then analyzed using single- and multivariate Cox regression, linear regression, and stratified analysis to identify their clinical effects. Threshold effect analysis was used to identify the optimal threshold for POSTN expression, and an in vitro experiment was conducted to evaluate the effect of POSTN on tumor cell growth and invasion.
resultsWGCNA analysis identified four genes strongly associated with LUAD recurrence. POSTN demonstrated good prediction performance for disease recurrence in both The Cancer Genome Atlas (TCGA) and GSE31210 datasets (Area Under the Curve (AUC)=0.693 and 0.743, respectively). Furthermore, POSTN was identified as an independent risk factor for disease recurrence in univariate and multivariate Cox regression analysis, and its expression level was found to be linearly related to disease recurrence in different populations. Threshold effect analysis indicated that a POSTN expression level of 12.5 was associated with a > 50% risk of recurrence within 1 year. In vitro experiments demonstrated that POSTN silencing could inhibit tumor cell proliferation and invasion.
conclusionPOSTN is positively correlated with the risk of early LUAD recurrence within 1 year after treatment, indicating its potential as a biomarker for predicting recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.